Back
to home » Treatment News » Top Stories
 February 10, 2012
|
FDA Panel: Qutenza Pain Patch for Neuropathy Not Ready for Approval
A U.S. Food and Drug Administration advisory committee voted unanimously against recommending the approval of a novel patch applied to the soles of the feet to remedy pain associated with neuropathy in people living with HIV. Though the patch is commercially available for the treatment of shingles-related neuropathy pain, the FDA’s Anesthetic and Analgesic Drug Products Advisory Committee’s review of two clinical trials of the Qutenza capsaicin patch involving HIV-positive volunteers did not find “substantial evidence of effectiveness.”
|
|
|
February 09, 2012
|
Antibiotics Losing Battle Against Gonorrhea
The last line of defense against gonorrhea is losing its effectiveness against the gonorrhea, according to a new article published February 9 in the The New England Journal of Medicine. With no new antibiotics effective against the sexually transmitted infection (STI) on the horizon, Gail Bolan, MD, of the U.S. Centers for Disease Control and her fellow authors, are worried about an upswing in gonorrhea samples showing to be less susceptible to cephalosporins—the only class of drugs active against the bacteria resistant to other standard treatments.
|
|
|
February 08, 2012
|
Merck Warns of Victrelis and HIV Protease Inhibitor Interactions
The hepatitis C protease inhibitor Victrelis (boceprevir) has some significant drug-drug interactions with common Norvir (ritonavir)?boosted protease inhibitor (PI) combinations, according to preliminary data from a clinical trial and a warning issued to health care providers by Merck on February 6.
|
|
|
FDA Questions Chili Pepper Patch Efficacy for HIV-Related Neuropathy
On the eve of an advisory committee meeting being held to determine whether or not to recommend U.S. Food and Drug Administration approval of NeurogesX’s Qutenza for the treatment of HIV-associated peripheral neuropathy, the FDA is questioning whether the capsaicin patch actually works.
|
|
|
HIV Diarrhea Drug Crofelemer Gets FDA Priority Review
The U.S. Food and Drug Administration (FDA) has granted Priority Review status to Salix Pharmaceuticals’ new drug application (NDA) for crofelemer tablets for HIV-associated diarrhea, according to a February 7 Salix announcement. Based on this review classification, the FDA must decide whether or not to approve the drug by June 5.
|
|
|
February 07, 2012
|
Spinal Cord Stimulation Shows Potential for Peripheral Neuropathy
Electrical stimulation of the spinal cord markedly reduced peripheral neuropathy (PN)associated pain in a man living with HIV who didn’t respond to more conventional PN therapies, according to a February 5 presentation at the 6th World Congress of the World Institute of Pain in Miami and reported by Medscape.
|
|
|
February 06, 2012
|
CDC Recommends HPV Vaccine for Boys and Young Men, Hep B Vaccine for Diabetics
It’s official: All males between 11 and 21 years of age should be vaccinated against human papillomavirus (HPV), a leading cause of oral, genital and anal cancers, according to new U.S. Centers for Disease Control and Prevention guidelines published February 3 in the health agency’s Morbidity and Mortality Weekly Report. HPV vaccination is also recommended for previously unvaccinated men between 22 and 26 years of age who have compromised immune systems, are HIV positive or have sex with other men.
|
|
|
February 02, 2012
|
Isentress, Intelence, Prezista Regimen Goes the Distance for HIV Treatment Veterans
A drug regimen containing Isentress (raltegravir), Intelence (etravirine) and Norvir (ritonavir)boosted Prezista (darunavir) has been shown to be “highly potent and durable in terms of efficacy and safety” in a French clinical trial involving heavily treatment-experienced people living with HIV. According to the research paper published ahead of print by the Journal of Acquired Immune Deficiency Syndromes (JAIDS), 88 percent of those using this regimen had undetectable viral loads after nearly two years of treatment.
|
|
|
February 01, 2012
|
Rising Caseloads, Lack of Funding Concern HIV Providers
Concerns over the rising amount of HIV cases and the decreasing amount of funding and reimbursement for HIV services were the two key findings from the second annual HealthHIV State of HIV Primary Care survey, according to a HealthHIV statement.
|
|
|
|
|
|
 |
FierceLittleGuy
WEST HOLLYWOOD
California
|
Muzungu
Granada Hills, SFV
California
|
sexyboy3086
orange county
California
|
Milwvirgo
Milwaukee
Wisconsin
|
| Click here to join POZ Personals! |
|
